Jasper Therapeutics, Inc. (JSPR) — Financial statements
Income statement, balance sheet, and cash flow for Jasper Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 63↑13.0% | 56↑7.8% | 52↑49.6% | 35↑36.2% | 25 | |
| General & Administrative Expenses | 21↑1.8% | 20↑19.6% | 17↑3.1% | 17↑45.2% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 21↑1.8% | 20↑19.6% | 17↑3.1% | 17↑45.2% | 11 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 84↑10.0% | 76↑10.7% | 69↑34.5% | 51↑39.0% | 37 | |
| Total Costs & Expenses | 84↑10.0% | 76↑10.7% | 69↑34.5% | 51↑39.0% | 37 | |
| Operating Results | ||||||
| Operating Income | -84↓10.0% | -76↓10.7% | -69↓34.5% | -51↓39.0% | -37 | |
| Depreciation & Amortization | 1↓23.1% | 1↑23.9% | 1↑13.6% | 0.98↑158.6% | 0.38 | |
| EBITDA | -83↓10.6% | -75↓10.5% | -68↓34.9% | -50↓37.8% | -36 | |
| EBIT | -84↓10.0% | -76↓10.7% | -69↓34.5% | -51↓39.0% | -37 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓65.6% | 5↓2.7% | 5↑641.7% | 0.70 | 0.00 | |
| Interest Income | 2↓65.6% | 5↓2.7% | 5↑641.7% | 0.70 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 8↑62.6% | 5↑13.1% | 4↓67.5% | 14↑118.1% | 6 | |
| Income Before Tax | -76↓6.4% | -71↓10.6% | -64↓71.1% | -38↓23.0% | -31 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -76↓6.4% | -71↓10.6% | -64↓71.1% | -38↓23.0% | -31 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -76↓6.4% | -71↓10.6% | -64↓71.1% | -38↓23.0% | -31 | |
| Bottom-Line Net Income | -76↓6.4% | -71↓10.6% | -64↓71.1% | -38↓23.0% | -31 | |
| EPS (Basic) | -3.95↑19.2% | -4.89↑20.9% | -6.18↑40.2% | -10.33↑61.6% | -26.89 | |
| EPS (Diluted) | -3.95↑19.2% | -4.89↑20.9% | -6.18↑40.2% | -10.33↑61.6% | -26.89 | |
| Weighted Average Shares | 19↑31.4% | 15↑39.7% | 10↑186.2% | 4↑220.3% | 1 | |
| Weighted Average Diluted Shares | 15↑5.1% | 15↑39.7% | 10↑186.1% | 4↑220.2% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.